Introduction
Caribou Biosciences, Inc. (Nasdaq: CRBU), a clinical-stage biopharmaceutical company focused on CRISPR genome editing, is set to host a webcast on November 3, 2025, to unveil new data from its allogeneic CAR-T cell therapy programs. The event will highlight updates from the ANTLER phase 1 clinical trial evaluating vispacabtagene regedleucel (vispa-cel) in patients with relapsed or refractory B cell non-Hodgkin lymphoma (r/r B-NHL) and the first clinical data from the CaMMouflage Phase 1 clinical trial evaluating CB-011 in patients with r/r multiple myeloma.
This announcement is of significant interest to investors, clinicians, and patients, as it provides insights into the potential of allogeneic CAR-T cell therapies in treating hematologic malignancies. The webcast will also cover the anticipated pivotal phase 3 trial design for vispa-cel and next steps for the continued clinical development of CB-011. The data shared has the potential to impact treatment strategies and patient outcomes in the future. The advancement of these therapies is crucial for expanding access to innovative cancer treatments.
Vispacabtagene Regedleucel (Vispa-cel)
Vispa-cel, previously known as CB-010, is an allogeneic anti-CD19 CAR-T cell therapy currently under evaluation in the ANTLER phase 1 clinical trial. This therapy targets patients with relapsed or refractory B cell non-Hodgkin lymphoma (r/r B-NHL). Notably, vispa-cel is designed with a PD-1 knockout, which aims to enhance CAR-T cell activity by limiting premature CAR-T cell exhaustion. The FDA has granted vispa-cel Regenerative Medicine Advanced Therapy (RMAT), Orphan Drug, and Fast Track designations for B-NHL.
According to Caribou Biosciences, vispa-cel is the first allogeneic CAR-T cell therapy in the clinic with a PD-1 knockout. The ANTLER trial is designed to assess the safety and efficacy of vispa-cel in patients who have failed previous treatments for B-NHL. The trial is registered under .
CB-011: An Allogeneic Anti-BCMA CAR-T Cell Therapy
CB-011 is an allogeneic anti-BCMA CAR-T cell therapy being evaluated in the CaMMouflage Phase 1 trial for patients with relapsed or refractory multiple myeloma (r/r MM). Caribou Biosciences states that CB-011 is engineered with an immune cloaking strategy, featuring a B2M knockout and insertion of a B2M–HLA-E fusion protein to blunt immune-mediated rejection. The FDA has granted CB-011 Fast Track and Orphan Drug designations.
The CaMMouflage trial focuses on determining the safety and efficacy of CB-011 in patients with r/r MM. The trial aims to overcome immune rejection challenges typically associated with allogeneic cell therapies. Additional details about the CaMMouflage trial can be found at .
About Caribou Biosciences, Inc.
Caribou Biosciences is a clinical-stage biopharmaceutical company leveraging CRISPR genome editing to develop transformative therapies. The company’s Cas12a chRDNA technology enables precision in creating cell therapies designed to improve activity against devastating diseases. Caribou is focused on advancing vispa-cel and CB-011 as off-the-shelf CAR-T cell therapies, aiming to provide broad access and rapid treatment for patients with hematologic malignancies.
Caribou Biosciences is dedicated to developing innovative therapies through its genome-editing platform. The company aims to address critical unmet needs in cancer treatment. To learn more, follow the Company @CaribouBio and visit .
Webcast Information
Caribou Biosciences will host a live webcast on Monday, November 3, 2025, beginning at 8:00 am ET. The webcast will be accessible via the Caribou website on the page. An archived version will be available for 30 days following the event.
Investors, analysts, and other interested parties are encouraged to participate in the webcast to gain insights into the latest developments in Caribou’s CAR-T cell therapy programs. The webcast will provide a platform to understand the potential impact of these therapies on the treatment of lymphoma and multiple myeloma.
CRBU Stock Performance
As of November 2, 2025, Caribou Biosciences’ stock (CRBU) is showing positive movement. According to the article, the stock is up by +4.31%. This reflects investor confidence in the company’s ongoing clinical trials and potential therapies. Investors should monitor the stock for further updates following the data release during the webcast.
The stock performance is crucial as it indicates the market’s perception of the company’s future prospects. Positive data from the clinical trials can significantly impact investor sentiment. Keeping an eye on CRBU stock can provide valuable insights into the company’s overall health and potential for growth.
Conclusion
Caribou Biosciences is poised to present significant data updates from its ANTLER and CaMMouflage clinical trials. The webcast on November 3, 2025, will provide a comprehensive overview of vispa-cel and CB-011, two allogeneic CAR-T cell therapies targeting lymphoma and multiple myeloma. The company’s innovative approach to genome editing and immune cloaking could pave the way for more effective and accessible cancer treatments.
Investors and clinicians alike should closely follow these developments, as they may influence future treatment paradigms. Caribou Biosciences’ commitment to advancing transformative therapies underscores its potential to make a substantial impact on the lives of patients with devastating diseases. The upcoming data release and pivotal trial design will be critical milestones for the company and the broader field of cell therapy.
Leave a Reply